We are live on ! Find out more
COEPW

Coeptis Therapeutics Warrants

Delisted

COEPW was delisted on the 24th of April, 2026.

10 hedge funds and large institutions have $6.28K invested in Coeptis Therapeutics Warrants in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more capital invested

Capital invested by funds: $4.63K → $6.28K (+$1.64K)

3.91% more ownership

Funds ownership: 0%3.91% (+3.9%)

9% less funds holding

Funds holding: 1110 (-1)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
10
Holders Change
-1
Holders Change %
-9.09%
% of All Funds
0.12%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
1
Reduced
2
Closed
3
Calls
Puts
Net Calls
Net Calls Change

COEPW Hedge Fund Activity: Q1 2026 in Review

10 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in Coeptis Therapeutics Warrants (COEPW) for Q1 2026, worth a combined $6.28K — up 35% from $4.63K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of COEPW and 2 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.

The largest buyer was Meteora Capital, opening a new position worth an estimated $1.38K. The largest seller was Landscape Capital Management, exiting entirely with an estimated $346 sold.

  • 10 institutional investors held Coeptis Therapeutics Warrants (COEPW) as of Q1 2026, down from 11 in Q4 2025.
  • Funds reported $6.28K of Coeptis Therapeutics Warrants stock for Q1 2026, up 35% quarter-over-quarter.
  • 2 funds opened new Coeptis Therapeutics Warrants positions in Q1 2026 and 3 closed out, a net change of -1 holder.
  • The largest Coeptis Therapeutics Warrants buyer in Q1 2026 was Meteora Capital, an estimated $1.38K added.
  • The largest Coeptis Therapeutics Warrants seller in Q1 2026 was Landscape Capital Management, an estimated $346 sold.

Based on aggregated 13F filings for Q1 2026.